Personalized immune-cell therapy targeting B7-H3 for ovarian cancer
Targeting B7-H3 in ovarian cancer
['FUNDING_R01'] · UNIV OF NORTH CAROLINA CHAPEL HILL · NIH-11260197
Testing a personalized CAR-T immune-cell treatment given into the abdomen to fight ovarian cancer that expresses B7-H3.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIV OF NORTH CAROLINA CHAPEL HILL (nih funded) |
| Locations | 1 site (CHAPEL HILL, UNITED STATES) |
| Trial ID | NIH-11260197 on ClinicalTrials.gov |
What this research studies
You would have your own immune cells collected and reprogrammed in a lab to recognize a protein called B7-H3 that many ovarian tumors carry. The modified CAR-T cells would be placed directly into the belly (intraperitoneally) so they reach tumor sites in the pelvis and abdomen. The main goal is to see whether this personalized treatment is safe and can reduce tumors, based on encouraging lab and animal results. The team at UNC Chapel Hill has regulatory approval and clinical-grade materials ready to make the cells.
Who could benefit from this research
Good fit: Adults with advanced or recurrent ovarian cancer whose tumors express B7-H3 and who can undergo blood cell collection and intraperitoneal therapy are the most likely candidates.
Not a fit: Patients whose tumors lack B7-H3, who cannot tolerate leukapheresis or intraperitoneal procedures, or who have serious coexisting illnesses may not benefit from this treatment.
Why it matters
Potential benefit: If successful, the treatment could shrink ovarian tumors and provide a new option for patients whose cancers express B7-H3.
How similar studies have performed: CAR-T therapies have produced dramatic results in blood cancers, but success in solid tumors like ovarian cancer is still limited, so this approach is relatively novel though supported by promising preclinical data.
Where this research is happening
CHAPEL HILL, UNITED STATES
- UNIV OF NORTH CAROLINA CHAPEL HILL — CHAPEL HILL, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: DOTTI, GIANPIETRO — UNIV OF NORTH CAROLINA CHAPEL HILL
- Study coordinator: DOTTI, GIANPIETRO
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.